Respiratory Tract Diseases
Diseases involving the RESPIRATORY SYSTEM.
Subtype terms (15)
More specific conditions that are subtypes of Respiratory Tract Diseases in the MeSH hierarchy.
- Bronchial Diseases
20 drugs (16 approved, 4 experimental)
- Ciliary Motility Disorders
9 drugs (6 approved, 3 experimental)
- Granuloma, Respiratory Tract
- Laryngeal Diseases
15 drugs (14 approved, 1 experimental)
- Lung Diseases
425 drugs (276 approved, 149 experimental)
- Nose Diseases
8 drugs (6 approved, 2 experimental)
- Pleural Diseases
10 drugs (7 approved, 3 experimental)
- Respiration Disorders
10 drugs (8 approved, 2 experimental)
- Respiratory Hypersensitivity
5 drugs (4 approved, 1 experimental)
- Respiratory System Abnormalities
2 drugs approved
- Respiratory Tract Fistula
- Respiratory Tract Infections
303 drugs (149 approved, 154 experimental)
- Respiratory Tract Neoplasms
29 drugs (19 approved, 10 experimental)
- Thoracic Diseases
19 drugs (17 approved, 2 experimental)
- Tracheal Diseases
9 drugs approved
Drugs by status
Approved for this indication (6)
Phase 4 trials (6)
Phase 3 trials (27)
- sodium nitrite
- ciclesonide
- ambroxol
- acetylcysteine
- calfactant
- ketamine
- gemcitabine
- beclomethasone
- pembrolizumab
- pemetrexed
- linagliptin
- carboplatin
- siltuximab
- bevacizumab
- tocilizumab
- vinorelbine
- autologous microbiome
- inactivated influenza vaccine
- influenza vlp vaccine
- docetaxel
- tranexamic acid
- cisplatin
- type-7 adv vaccine
- ralinepag
- type-4 adv vaccine
- camrelizumab
- pralsetinib
Phase 2 trials (30)
- vitamin d3
- burlulipase
- cc-90001
- imatinib
- flulaval
- lapatinib
- osimertinib
- pf-00610355
- pf-03635659
- aluminum hydroxide
- alectinib
- gla-se
- vapendavir
- gefitinib
- allogeneic adipose derived mesenchymal stem cell
- adebrelimab
- erlotinib
- rsv f vaccine
- etoposide
- dexamethasone
- interferon alpha-2b
- sintilimab
- tezepelumab
- COVID-19 convalescent plasma
- cynk-001
- blu-701
- blu-945
- mrg001
- blu-451
- ah5n6c
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (24)
- AstraZeneca
- Novartis
- Bayer
- Serum Institute of India Pvt. Ltd.
- Boehringer Ingelheim
- United States Army
- United States Navy
- Kyung Hee University
- University of Ottawa
- University of Tehran
- University of Bern
- University of Zurich
- University of Modena and Reggio Emilia
- Icahn School of Medicine at Mount Sinai
- Leiden University
- Medical University of Vienna
- Isfahan University
- University of New South Wales
- University of Western Ontario
- Rassoul Akram Hospital
- Yuhan Pharmaceutical Company
- Government of Kyrgyzstan
- Ross University School of Veterinary Medicine
- Schweizerischer Nationalfonds
Organization Involved with Phase 3 Indications (26)
- Ferrosan AS
- Takeda
- United Therapeutics
- Pfizer
- Sanofi
- Zambon
- Arena Pharmaceuticals
- Blueprint Medicines Corporation
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Medicago
- Duramed Research
- Chr Hansen
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Federal University of Rio Grande do Sul
- Johns Hopkins University
- University of Southern Denmark
- Tel Aviv University
- University of Copenhagen
- University of Turin
- Federal University of Pernambuco
- University of Sao Paulo
- Department of Veteran Affairs
- EUSA
- Syneos Health
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (49)
- Celgene
- Amgen
- Debiopharm
- Cumberland Pharmaceuticals
- Immune Design
- INC Research
- Innovent Biologics (Suzhou) Co. Ltd.
- Lung Biotechnology PBC
- Nordmark Arzneimittel GmbH & Co. KG
- Parexel
- Amarillo Biosciences, Inc.
- Pulmocide Ltd
- Fundación Pública Andaluza
- Harvard University
- Institut National de la Santé Et de la Recherche Médicale, France
- McGill University
- Texas Tech University
- University of Leicester
- University of Rochester
- University of Seville
- University of Southern California
- Capital Medical University
- Columbia University
- Fudan University
- University of Cincinnati
- Food and Drug Administration
- inVentiv
- Centre de Recherche St-Louis, Quebec, Canada
- Topstone Research, Toronto, Canada
- Omnispec Clinical Research Inc, Mirabel, Canada
- +19 more
Organization Involved with Phase 1 Indications (13)
- Biosearch S.A.
- Inovio Pharmaceuticals
- Regend Therapeutics
- University of Manitoba
- Soochow University
- Canadian Science Centre for Human and Animal Health
- National Microbiology Laboratory, Canada
- Inha University
- Government of Canada
- Tianjin Cansino Biotechnology Inc
- Hyundai
- Health Sciences Centre Foundation, Manitoba
- Synspira, Inc.
Organization Involved with Other Experimental Indications (17)
- Fundacion Infant
- University of London
- Guangzhou Medical University
- Katholieke Universiteit Leuven
- University of Leeds
- University of Manchester
- University of Nottingham
- University of York
- Cardiff University
- Université catholique de Louvain
- University of Applied Sciences of Western Switzerland
- University of Lille
- School of Gestion and Engineering Vaud
- National Council of Scientific and Technical Research, Argentina
- Yorkshire Cancer Research
- Centro de Excelencia en Productos y Procesos Córdoba
- Química Luar SRL